Shares of Peregrine Pharmaceuticals soared up to 33% intraday before closing with a still impressive 19% gain, thanks to the announcement that the FDA green-lit bavituximab's phase 3 non-small-cell lung cancer trial.
http://www.fool.com/investing/general/2013/05/20/fda-green-light-surprise-share-surge.aspx
http://www.fool.com/investing/general/2013/05/20/fda-green-light-surprise-share-surge.aspx
No comments:
Post a Comment